Abstract. Poly (aspartic acid-co-lactic acid) (PAL) has been investigated as a new biodegradable material for Drug Delivery Systems (DDS). Similar to the poly (lactic acid-co-glycolic acid) (PLGA) nanospheres, the PAL nanospheres can control-release encapsulated drugs by hydrolysis and adhere to the mucous membranes to improve the drug absorption. In this study, the vitamin encapsulated PAL nanospheres were applied on mice to examine their effect on tumor metastasis and safety as an injectable DDS material for anti-cancer and other drugs. In the experiment, 6 C57BL/6 mice per group were intravenously administered with B16BL6 melanoma cells (1x10^5 per mouse) and non-encapsulated PAL nanospheres or pro-vitamin encapsulated nanospheres respectively, while the control group was administered with B16BL6 cells alone. Two weeks later, the lungs of the mice were excised and metastatic foci on the lung surface were counted. The melanoma cell metastasis to lungs was prevented by intravenous co-injection of B16BL6 melanoma cells with 1.7 μg of pro-vitamin E encapsulated PAL nanospheres. Its metastatic foci count (mean ± SD) was 127±80, which was better than the control (246±95, p<0.02). Also, applying the pro-vitamin C and pro-vitamin A encapsulated PAL nanospheres as well as the non-encapsulated PAL nanospheres slightly decreased the number of metastasis colonies in the lungs as compared to that of the control. These results suggested that PAL nanospheres did not promote the lung metastasis of B16BL6 melanoma cells. Thus, the PAL nanospheres are safe material for injection applications.

Introduction

Infiltration through basement membranes of cancer cells is essential for causing metastasis to other organs (1). When using a new carrier in the DDS for anti-cancer applications, for safety reasons, it is very important to assess the effect of the carrier on cancer metastasis. Poly (aspartic acid-co-lactic acid) (PAL) (2) is a bioabsorbable, biodegradable polymer developed over the last few years. The authors have optimized a process to efficiently encapsulate drugs in the sub-micron sized PAL nanospheres (3). These PAL nanospheres have about the same particle sizes as the poly (lactic acid-co-glycolic acid) (PLGA) nanospheres (4,5), which can improve the absorption of drugs and sustain their pharmacological effects. Because PAL nanospheres can control-release the drugs by hydrolysis similarly to the PLGA nanospheres, they are potential carriers of DDS for the transpulmonary (6-8) and transdermal (9,10) drug administration. Furthermore, since the glass transition temperature of PAL nanospheres [aspartic acid:lactic acid = 17:83, weight-average molecular weight (Mw) = 9,000] is ~60˚C, which is higher than the 45˚C of PLGA nanospheres (lactic acid:glycolic acid = 75:25, Mw = 20,000), PAL nanospheres are more advantageous in processing flexibility and storage stability; therefore, they can likely be applied in a wider range of applications. When designing new DDS with PAL nanospheres, it is important to assess the effect of these nanospheres on cancer metastasis at the development stage. Particularly, it was reported that the invasion and metastasis of cancer cells could be influenced by body conditions (11), such as blood hormones, and the routes of drug administration.

With an effort to adapt PAL nanospheres for transdermal applications, their safety of use was first investigated. Using the Boyden chamber method (12-14), which mimics human basement membranes, this study investigated the effect of a liquid mixture containing mouse melanoma B16BL6 cells.
and PAL nanospheres on the membrane invasion. It was found that the PAL nanospheres could inhibit melanoma membrane invasion (15). Cancer cells manage to infiltrate basement membranes by the following three steps: 1) thigmotaxis and adherence to the basement membranes, 2) production of matrix metalloprotease (MMP) precursors to dissolve the basement membranes, and 3) penetration of the basement membranes by means of cell deformation (16). It appeared that PAL nanospheres inhibited the activation of MMP precursors, because their free carboxyl radicals from the aspartic acid constituent had preferential bonding with the positively charged zinc ions, which were the active centers of MMP precursors. Furthermore, experimental results showed no promotion of the melanoma metastasis to other organs even though applying PAL nanospheres externally to the skin with a melanoma. Therefore, the PAL nanospheres are safe to use for transdermal drug delivery applications without the concern of cancer metastasis.

Taking one step further, this study was to assess the safety of using PAL nanospheres as a DDS carrier for anti-cancer agents and other drugs in the intravenous injection applications. The experiment was designed to investigate the effects of PAL nanospheres on cancer cell metastasis to the lungs when intravenously administering them together with mouse melanoma B16BL6 cells. The mouse melanoma B16BL6 cells were reported having a great tendency to metastasize to the lungs via the tail vein in a model study that created experimental lung metastatic tumors.

The experimental results suggested that intravenously administering PAL nanospheres were safe and did not promote the metastasis of melanoma cells to the lungs.

Materials and methods

Cell lines. The B16BL6 mouse melanoma cells (University of Texas M.D. Anderson Hospital, Houston, TX) were selected as the model cancer cells. The B16BL6 mouse melanoma cells have often been employed in the cancer metastasis experiments, because they quickly and selectively metastasize to the lungs after administration and proliferate in a short time.

Materials. PAL used in the experiment was the PAL15 made by Mitsui Chemicals, with an aspartic acid to lactic acid ratio of 17:83 and a weight-average Mw of 9,000. As a comparison, PLGA (PLGA7520; Wako Pure Chemical Industries) had a lactic acid to glycolic acid ratio of 75:25 with a weight-average Mw of 20,000. Model drugs encapsulated in the PAL nanospheres were: 1) Ascorbyl tetraisopalmitate (VC, Nikko Chemicals; a pro-vitamin C derivative), 2) DL-α-tocopheryl acetate (VE, Eisai; a pro-vitamin E derivative), and 3) retinol palmitate (VA, Riken Vitamin; a pro-vitamin A derivative).

Polyvinyl alcohol (PVA, Kuraray; PVA403) was used as the dispersant for the production of PAL and PLGA nanospheres. In addition, negative control agent for melanoma lung cancer metastasis was ascorbyl tetraisopalmitate (VC); and, positive control agent for melanoma lung cancer metastasis was phorbol-12-myristate-13-acetate (PMA, Sigma Aldrich, Japan).

Preparation of PAL nanospheres. PAL nanospheres were prepared by the emulsion solvent diffusion (ESD) method, the same technique was used to prepare PLGA nanospheres (4,5). After dissolving 2 g of PAL in 20 ml of acetone, 10 ml of ethanol were added to make a polymer solution. The solution was then dropped into 50 ml of 2% PVA aqueous solution at 40˚C with a speed of 400 rpm. At this point, nano droplets were formed in the emulsion by the self-emulsification at the droplet interface due to rapid diffusion and counter diffusion of the solvents. After evaporating the organic solvents and removing excess PVA by washing and centrifugation, the remainder was freeze-dried to obtain a dry PAL nanosphere powder (i.e. sample group iv). With the same procedure, vitamin encapsulated PAL nanospheres could be produced by adding 0.2 g of VC, VE, or VA separately in the above polymer solution.

The encapsulation ratio of VC, VE, and VA in the encapsulated PAL nanospheres was 8.6, 11.0, and 7.5% representing the sample group i, ii, and iii, respectively. After freeze-drying, the nanosphere particles were re-dispersed in the purified water for particle size measurement by the dynamic light-scattering method. All particles were spherical
shape and had an average particle size of ~200 nm with narrow particle size distribution. Fig. 1 shows the scanning electron microscope (SEM) photos of VC loaded PAL nanospheres, and Fig. 2 shows its particle size distribution. In addition, a control sample of non-encapsulated PLGA nanospheres having an average particle size of 260 nm (i.e. sample group v) was also prepared for the experiment to assess the influence of different carrier materials on the test results.

Cancer metastasis assay (17). The following describes the procedures used to study the possibility of cancer metastasis stimulated by a single dose of PAL nanospheres. 1) Trypsin-treated B16BL6 mouse skin melanoma cells (MEM/10% FCS, 1x10^5 cells) in their logarithmic growth phase were incubated with the nanospheres (from groups i to v), negative control agent, or positive control agent separately in a rotator for 1 h at 37°C. 2) The test solution prepared in 1) was injected into C57BL/6 mice (eight-week-old male, n=6 to 8/test group) via its tail vein. 3) The mice were terminated 11 or 14 days after inoculation with the melanoma cells. Their lungs were excised, rinsed and fixed in the Bouins solution. The metastatic foci on the lung surfaces were counted (mean ± SD) under a stereomicroscope. The metastatic foci count was then compared with that of the control group, which was not given test substance.

The doses of the non-encapsulated PAL nanospheres (group iv) and the non-encapsulated PLGA nanospheres control (group v) applied in the experiment were based on the commercial leupline™ for injection (Takeda Chemical Industries, Ltd.: packaging insertion of leuplin for injection 1.88, 3.75; kit 1.88 and kit 3.75), which contains PLGA microspheres to treat cancers such as prostate gland and postmenopausal breast cancer. Specifically, a single dose of leupline was 33.75 mg of PLGA per 60 kg of patient. Taking the proportion for an average weight of the C57BL/6 mouse (20 g at eight weeks old), it came to 11.25 μg of PLGA per 20 g. In the experiment, the dose was set at 15 μg/20 g to positively confirm the safety of the nanospheres. In addition, a dose as high as 400 μg/20 g (>25 times the standard dose) was also tested.

The doses of the vitamin derivative encapsulated PAL nanospheres (from groups i to iii) were based on the commercially available functional beauty essences (10) containing PLGA nanospheres, whose safety was previously confirmed. Specifically, by determining the concentration of vitamin derivatives in the beauty essence and the dose of the non-encapsulated PAL nanospheres, the required amount of vitamin derivatives in the PAL nanospheres could be calculated.

Results and Discussion

Fig. 3 shows the number of metastatic cancer nodules in the lungs measured 11 days after intravenously administering melanoma cells without any nanospheres (control group), and with non-encapsulated PAL nanospheres (group iv) as well as non-encapsulated PLGA nanospheres (group v). Fig. 4 shows representative lung tissue samples from each test group.
Effect of administering negative control and positive control. To validate the in vitro assay, two additional groups were tested. They were the negative control group (group N) administered with VC, which is known to suppress melanoma metastasis to the lungs (18); and, the positive control group (group P) administered with phorbol-12-myristate-13-acetate (PMA), which is a powerful cancer promoter (19). The evaluation procedures of the groups N and P were the same as those mentioned above in the cancer metastasis assay section. The VC dosages applied herein were the same as the dosages of Asc2P (ascorbic acid-2-O-phospate Mg salt) and Asc2G (ascorbic acid-2-O-α-D-glycoside) used in our previous evaluation system, which were proven effective to repress melanoma invasion (1). Also, PMA dosages were set at the same level as those used in the chemo-invasion assay (19), which showed positive invasion of human hepatocellular carcinoma (HCC), SNU-387 and SNU-398.

The number of cancer nodules in the control group was 153±28 (mean ± SD). Cancer cell colonies were found on the surfaces of five lung lobules as grains colored black by melanin pigment. When intravenously administering VC to group N with melanoma cells, the number of cancer nodules was reduced to 62±35 and 112±41 with p<0.01 at the concentrations of 300 and 500 μM, respectively.

It is believed that the VC taken by the melanoma cells during incubation in the rotator could suppress cancer invasion. It appeared that the reduced vitamin C converted from VC by esterase eliminated the reactive oxygen species and free radicals in the melanoma cells. This, in turn, decreased the cancer cell mobility and thigmotaxis, and limited the production of the MMP-2 and MMP-9 needed for cancer invasion (1).

When intravenously administering PMA to group P with melanoma cells, the number of cancer nodules found was 177±65 (mean ± SD) at concentrations of 0.1 μM. It seemed that the cancer cell invasion to the lung tissue was stimulated by the carcinogenic promotion of PMA when it was incubated with melanoma cells in the rotator. It is believed that the PMA activated the protein kinase C (PKC), a signal trans-ferring material in a cancer cell, to cause the production of MMP-9. The MMP-9, in turn, promoted cancer metastasis and resulted in a marked increase of cancer nodules in the lungs.

Therefore, this method of assaying by intravenously injecting each agent and melanoma cells at the same time is an appropriate method for assaying the capability of melanoma cells to metastasize to the lungs.

Effect of administering non-encapsulated PAL and PLGA nanospheres. The number of lung cancer nodules (mean ± SD) from the test group receiving non-encapsulated PAL nanospheres along with melanoma cells was 167±9.3 with a dose of 15 μg/mouse, and 76±45 (p<0.05) with a dose of 400 μg/mouse.
Similarly, in the non-encapsulated PLGA nanosphere group, we discerned no significant difference in the cancer nodule count from the control group regardless of the particle size or concentration administered. The PLGA nanospheres were proven safe for hypodermic injection. This indicated that PAL nanosphere would have no adverse effect.
on the cancer metastasis and it is safe to use as a DDS carrier.

Furthermore, non-encapsulated PAL nanospheres without melanoma cells were intravenously administered to the mouse. There was no observation of cancer cells in the excised lungs (n=1). This result indicated that the lung cancer found in this assay was solely caused by the intravenous administration of melanoma cells. The PAL nanospheres themselves are not carcinogenic.

**The effects of vitamin derivative encapsulated PAL nanospheres.** Fig. 5 shows the number of metastasized lung cancer nodules found in the control group and in the groups given vitamin derivative encapsulated PAL nanospheres mixed with melanoma cells (from groups i to iii) 14 days after intravenously administering the preparations. Fig. 6 shows representative lung tissues from each group. While the control group had cancer nodules at 246±95, those from the groups with VC, VE, and VA encapsulated PAL nanospheres were: from low to high doses, 193±74 (group i -1), 225±59 (group i -2), 127±80 (group ii -1), 213±42 (group ii -2), 226±30 (group iii -1) and 177±63 (group iii -2). It appeared that there was no dependence on the dose size. Except group ii -1, there was no significant difference between the control group and other test groups. This result confirms that vitamin derivative encapsulated PAL nanospheres did not have adverse effect on the cancer cell metastasis in comparison to the control group.

In conclusion, to assess the safety of using PAL nanospheres, a biocompatible, bioabsorbable polymer, as a DDS carrier for intravenous applications, was applied to B16BL6 mouse melanoma cells to investigate their effect on the cancer cell metastasis in a mouse model. 1) It was found that both non-encapsulated PAL nanospheres and vitamin derivative encapsulated PAL nanospheres exhibited no adverse effect on the cancer cell metastasis. 2) Vitamin E encapsulated PAL nanospheres exhibited ~50% suppression effect on the cancer cell metastasis in comparison to the control group.

Results obtained within the scope of this study suggested that the PAL nanospheres are safe to use for intravenous injection from the perspective of cancer cell metastasis.

**References**